Field Notes on Entering the ANZ MedTech Market.
Why MedTech Founders Are Running Clinical Trials in New Zealand
Why New Zealand is becoming the preferred jurisdiction for early-phase MedTech clinical trials, and how its approval process, cost structure, and ICH-GCP alignment create a practical pathway for founders.
TGA Classification Rules: The Framework That Decides Your Regulatory Pathway
How TGA's risk-class system shapes your conformity assessment route, clinical evidence burden and ARTG timeline, and where sponsors most often misclassify.
ANZ MedTech Market Entry: The Regulatory-first Approach That Actually Works
Why ANZ entry needs two regulatory tracks in parallel, how to sequence distributor and reimbursement decisions, and where launches typically slip.
Distributor vs direct: choosing your ANZ commercial model
The decision overseas MedTech leaders agonise over most. Here's the framework we use with clients to get to an answer in a week, not a quarter.
TGA vs Medsafe: what actually differs
A practical comparison for sponsors and regulatory directors weighing whether to file in both jurisdictions in the same cycle.
An ANZ MedTech market-entry primer
What overseas founders consistently underestimate when they decide to launch into Australia and New Zealand, and how to sequence the first 12 months.